ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT and other gene editing technologies developed after 12 years of R&D at Applied Stem Cells, Inc. The company’s therapeutic development pipeline includes several preclinical stage programs in gene and cell therapy progressing into clinical stage in 2022 focusing on several blood disorders. We are dedicated to discovering, developing and delivering cures for intractable and rare diseases. We are passionate about helping patients lead more hopeful, healthier and happier lives.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
To provide cures to patients with intractable diseases through innovative technologies and therapeutics that are both groundbreaking and safe.
ASC Therapeutics strives to discover, develop, and deliver gene and cell treatments to cure intractable and emerging diseases.
Our diverse team has decades of experience in cutting edge stem-cell and gene therapy research. Together we strive to be innovators to provide platforms to revolutionize the way diseases are treated.
ASC Therapeutics is an independent, fully incorporated biopharmaceutical company with dedicated scientists and industry veterans with a strong belief in gene and cell therapy, the future for treating rare disease.
The company leverages over 12 years of experience by Applied StemCell, Inc., a separate entity, focused on developing and improving gene editing and stem cell technologies.
Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies.
Not only do we have experienced teams for discovery research, CMC, pre-clinical and clinical development, we also collaborate with leading academic and industry partners around the world to advance and expand our product pipeline. Building upon our deep knowledge in stem cell, gene therapy and genome editing technology, we are devoted to discovering, developing and delivering cures for intractable diseases.